Skip to main content
SpringerLink
Log in

New safety information for epoetin-α, darbepoetin-α

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Health Canada.Important safety information and new prescribing information for the erythropoiesis-stimulating agents, Aranesp (Rm) (darbepoetin alfa) and EPREX* (epoetin alfa). Internet Document: [5 pages], 16 Apr 2007. Available from: URL: http://www.hc-sc.gc.ca

  2. Health Canada.Important Safety Information and New Prescribing Information for the Erythropoiesis-Stimulating Agents, Aranesp(Rm) (darbepoetin alfa) and EPREX* (epoetin alfa). Media Release: 19 Apr 2007. Available from: URL: http://www.hc-sc.gc.ca

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

New safety information for epoetin-α, darbepoetin-α. React. Wkly. 1149, 1 (2007). https://doi.org/10.2165/00128415-200711490-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711490-00001

Keywords

Search

Navigation